KR20160017131A - 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도 - Google Patents

엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도 Download PDF

Info

Publication number
KR20160017131A
KR20160017131A KR1020167002567A KR20167002567A KR20160017131A KR 20160017131 A KR20160017131 A KR 20160017131A KR 1020167002567 A KR1020167002567 A KR 1020167002567A KR 20167002567 A KR20167002567 A KR 20167002567A KR 20160017131 A KR20160017131 A KR 20160017131A
Authority
KR
South Korea
Prior art keywords
glu
subunit
seq
amino acid
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167002567A
Other languages
English (en)
Korean (ko)
Inventor
데니스 부비에
티보 크레핀
로브 뤼그록
알렉산더 디아스
스테판 쿠삭
Original Assignee
유럽피안 몰레큘러 바이올로지 래보러토리
센트르 내쇼날 드 라 레체르체 싸이언티피크 디렉션 드 라 폴리티크 인더스트리엘르
유니버시티 죠셉 푸어리어 필리알르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유럽피안 몰레큘러 바이올로지 래보러토리, 센트르 내쇼날 드 라 레체르체 싸이언티피크 디렉션 드 라 폴리티크 인더스트리엘르, 유니버시티 죠셉 푸어리어 필리알르 filed Critical 유럽피안 몰레큘러 바이올로지 래보러토리
Publication of KR20160017131A publication Critical patent/KR20160017131A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G06F19/12—
    • G06F19/16—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
KR1020167002567A 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도 Ceased KR20160017131A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20325908P 2008-12-19 2008-12-19
US61/203,259 2008-12-19
PCT/EP2009/009161 WO2010069600A2 (en) 2008-12-19 2009-12-18 Polypeptide fragments comprising endonuclease activity and their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117013955A Division KR20110127114A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩타이드 단편 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20160017131A true KR20160017131A (ko) 2016-02-15

Family

ID=41668407

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020167002567A Ceased KR20160017131A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020167026244A Ceased KR20160113335A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020177014264A Abandoned KR20170061193A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020167002571A Abandoned KR20160017132A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020117013955A Ceased KR20110127114A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩타이드 단편 및 이의 용도

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020167026244A Ceased KR20160113335A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020177014264A Abandoned KR20170061193A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020167002571A Abandoned KR20160017132A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩티드 단편 및 이의 용도
KR1020117013955A Ceased KR20110127114A (ko) 2008-12-19 2009-12-18 엔도뉴클레아제 활성을 포함하는 폴리펩타이드 단편 및 이의 용도

Country Status (13)

Country Link
US (3) US20120108493A1 (https=)
EP (2) EP2379715B1 (https=)
JP (3) JP2012512633A (https=)
KR (5) KR20160017131A (https=)
CN (1) CN102449144B (https=)
AU (1) AU2009328502B2 (https=)
BR (1) BRPI0923134A2 (https=)
CA (1) CA2745532A1 (https=)
ES (1) ES2604227T3 (https=)
IL (1) IL213360A0 (https=)
MX (1) MX2011006539A (https=)
SG (1) SG172239A1 (https=)
WO (1) WO2010069600A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101792745B (zh) 2009-02-04 2014-09-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构
US8859290B2 (en) * 2011-07-22 2014-10-14 Rutgers, The State University Of New Jersey Inhibitors of influenza endonuclease activity and tools for their discovery
JP6570448B2 (ja) * 2013-10-02 2019-09-04 学校法人 久留米大学 インフルエンザウイルス阻害薬
CN109477081A (zh) * 2016-07-07 2019-03-15 欧洲分子生物学实验室 结合细胞Pol Ⅱ C末端结构域（CTD）的病毒多肽片段及其用途
JP6918305B2 (ja) * 2017-03-10 2021-08-11 地方独立行政法人神奈川県立産業技術総合研究所 インフルエンザウイルスの増殖を阻害するモノクローナル抗体
CN114496063B (zh) * 2022-01-13 2023-05-23 北京博康健基因科技有限公司 基于天然氨基酸序列的信号肽设计与二级结构从头算建模方法和装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482414B1 (en) * 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
AU2001270033A1 (en) * 2000-06-23 2002-01-08 Wyeth Holdings Corporation Nucleotide sequence of influenza A/Udorn/72 (H3N2) genome
EP1549318B1 (en) * 2002-05-01 2010-02-17 Vertex Pharmaceuticals Incorporated Crystal structure of aurora-2 protein and binding pockets thereof
WO2004035812A2 (en) * 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
JP4739192B2 (ja) * 2003-05-02 2011-08-03 イーラン ファーマスーティカルズ、インコーポレイテッド Ｂａｃｅのグリコシル化変異体
US7439327B2 (en) * 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof

Also Published As

Publication number Publication date
IL213360A0 (en) 2011-07-31
CA2745532A1 (en) 2010-06-24
US20180010109A1 (en) 2018-01-11
US9890368B2 (en) 2018-02-13
AU2009328502B2 (en) 2015-02-05
AU2009328502A1 (en) 2011-07-14
EP2623590A3 (en) 2013-11-13
WO2010069600A2 (en) 2010-06-24
KR20160113335A (ko) 2016-09-28
JP2017205107A (ja) 2017-11-24
EP2379715A2 (en) 2011-10-26
CN102449144B (zh) 2015-08-26
EP2379715B1 (en) 2016-10-26
SG172239A1 (en) 2011-07-28
KR20160017132A (ko) 2016-02-15
US20150105315A1 (en) 2015-04-16
JP2012512633A (ja) 2012-06-07
WO2010069600A8 (en) 2011-07-21
MX2011006539A (es) 2011-10-21
KR20170061193A (ko) 2017-06-02
KR20110127114A (ko) 2011-11-24
CN102449144A (zh) 2012-05-09
BRPI0923134A2 (pt) 2017-03-28
EP2623590A2 (en) 2013-08-07
JP2016013124A (ja) 2016-01-28
US20120108493A1 (en) 2012-05-03
ES2604227T3 (es) 2017-03-03
WO2010069600A3 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
US9045248B2 (en) Soluble fragments of influenza virus PB2 protein capable of binding RNA-cap
US20180010109A1 (en) Polypeptide fragments comprising endonuclease activity and their use
US20180044649A1 (en) Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use
HK1163166B (en) Polypeptide fragments comprising endonuclease activity and their use
HK1163166A (en) Polypeptide fragments comprising endonuclease activity and their use
HK1183501A (en) Polypeptide fragments comprising endonuclease activity and their use
HK1179985A (en) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160128

Application number text: 1020117013955

Filing date: 20110617

PA0201 Request for examination
PG1501 Laying open of application
AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161028

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160331

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161028

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160531

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170227

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180129

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170825

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170227

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170126

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20161028

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160531

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160331